IQVIA™ Real-World Insights Bibliography

The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making
Author(s): Paul Cottu 1, Scott David Ramsey 2, Oriol Sol√†-Morales 3, Patricia A Spears 4, Lockwood Taylor 5
Affiliations(s): 1Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm, 75005, Paris, France. Electronic address: paul.cottu@curie.fr. 2Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M2-B232, Seattle, WA, 98155, USA. Electronic address: sramsey@fredhutch.org. 3Health Innovation Technology Transfer Foundation, Arag√≥ 60, E-08015, Barcelona, Spain. Electronic address: osola@fhitt.org. 48605 Carolingian Court, Raleigh, NC, 27615, USA. Electronic address: paspears88@gmail.com. 5Epidemiology, Real World Solutions at IQVIA, 4820 Emperor Boulevard, Durham, NC, 27703, USA. Electronic address: lockwood.taylor@iqvia.com.
Publication(s):  Breast. 2021 Dec 22;61:118-122. doi: 10.1016/j.breast.2021.12.015.
Document Type(s): Article,
Countries: France, Italy, USA,
Click here for the abstract
C:
Y:
Comparative Effectiveness & Health Technology Assessment, Drug safety, Oncology, Regulatory,
2022
  L:
A:
English
Review,
  Add to report
 
 
Real-world evidence to support regulatory decision making: New or expanded medical product indications
Author(s): Franklin JM, Liaw KL, Iyasu S, Critchlow CW, Dreyer NA.
Affiliations(s): 1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 2Center for Observational and Real-world Evidence, Merck & Co., Inc, Kenilworth, New Jersey, USA. 3Research & Development Strategy and Operations, Amgen, Thousand Oaks, California, USA. 4Real World Solutions, IQVIA, Cambridge, Massachusetts, USA.
Publication(s):  Pharmacoepidemiol Drug Saf . 2021 Jun;30(6):685-693. doi: 10.1002/pds.5222. Epub 2021 Mar 18.
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C:
Y:
Guidelines, Regulatory,
2021
  L:
A:
English
Real World Data, Real World Evidence,
  Add to report
 
 
Bridging the Gap Between RCTs and RWE Through Endpoint Selection
Author(s): Robert J LoCasale 1, Chris L Pashos 2, Ben Gutierrez 3, Nancy A Dreyer 4, Toby Collins 5, Alan Calleja 5, Michael J Seewald 6, Jonathan M Plumb 7, Johan Liwing 8, Maurille Feudjo Tepie 9, Sajan Khosla 10
Affiliations(s): 1Real World Evidence, Sanofi, Bridgewater, NJ, USA. 2AbbVie, Chicago, IL, USA. 3GSK, Philadelphia, PA, USA. 4IQVIA, Real-World Solutions, Cambridge, MA, USA. 5IQVIA, Real-World Solutions, London, UK. 6Novartis Pharma AG/Pharma Medical Affairs, Basel, Switzerland. 7Ferring Pharmaceuticals SA, St Prex, Switzerland. 8CellProtect Nordic Pharmaceuticals, Stockholm, Sweden. 9Center for Observational Research, Amgen, Cambridge, UK. 10Real-World Evidence Center of Excellence, AstraZeneca, Cambridge, UK. sajan.khosla@astrazeneca.com.
Publication(s):  Ther Innov Regul Sci . 2021 Jan;55(1):90-96. doi: 10.1007/s43441-020-00193-5. Epub 2020 Jul 6.
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C:
Y:
Regulatory,
2021
  L:
A:
English
Real World Data, Real World Evidence,
  Add to report
 
 
When Can We Trust Real-World Data To Evaluate New Medical Treatments?
Author(s): Gregory E Simon 1, Andrew B Bindman 2, Nancy A Dreyer 3, Richard Platt 4, Jonathan H Watanabe 5, Michael Horberg 6, Adrian Hernandez 7, Robert M Califf 8
Affiliations(s): 1Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA. 2Kaiser Foundation Health Plan and Hospitals, Redwood City, California, USA. 3IQVIA Real World Solutions, Durham, North Carolina, USA. 4Harvard Pilgrim Health Care Institute and Harvard Medical School, Hartford, Connecticut, USA. 5University of California Irvine School of Pharmacy and Pharmaceutical Sciences, Irvine, California, USA. 6Kaiser Permanente Mid-Atlantic Permanente Research Institute and Mid-Atlantic Permanente Medical Group, Rockville, Maryland, USA. 7Duke Clinical Research Institute, Durham, North Carolina, USA. 8Verily Life Sciences and Google Health, South San Francisco, California, USA.
Publication(s):  Clinical Pharmacology & Therapeutics 2022; 111(1):24-29, 2022/1
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C:
Y:
Regulatory,
2021
  L:
A:
English
Real World Data,
  Add to report
 
 
The impact of the new innovative algorithm in Italy
Author(s): Rova A1, Cioni L1, Urbinati D1
Affiliations(s): 1 IQVIA, RWI, Milan, Italy
Publication(s):  ISPOR 21st Annual European Congress, 10-14 November 2018, Barcelona, Spain
Document Type(s): Poster,
Countries: Italy,
C:
Y:
Health policy, Public Health, Regulatory,
2018
  L:
A:
English
  Add to report
 
 
The evolution of standard monitoring registries in the Italian market
Author(s): Cioni L1, Rova A1, Urbinati D1
Affiliations(s): 1 IQVIA, RWI, Milan, Italy
Publication(s):  ISPOR 21st Annual European Congress, 10-14 November 2018, Barcelona, Spain
Document Type(s): Poster,
Countries: Italy,
C:
Y:
Health policy, Public Health, Regulatory,
2018
  L:
A:
English
  Add to report
 
 
Off-Label Prescription of Drugs Compared to Prescription After Label Extension in Children for Germany
Author(s): Gohlke A, Kostev K, Kuschel AS
Affiliations(s): IQVIA Commercial GmbH & Co. OHG, Munich, Germany
Publication(s): 
Document Type(s): 
Countries: 
C:
Y:
Health policy, Pediatrics, Regulatory,
2018
  L:
A:
English
Utility analysis,
  Add to report
 
 
The impact of managed entry agreements on drug time to market in Italy
Author(s): Mantuano M1, Rova A1, Urbinati D1
Affiliations(s): 1 QuintilesIMS, Milan, Italy
Publication(s):  ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
Document Type(s): Poster,
Countries: Italy,
C:
Y:
Health policy, Regulatory,
2017
  L:
A:
English
Literature Review,
  Add to report
 
 
The impact of biosimilar launch on molecule price and pharmaceutical expense: the case of the insulin glargine in Italy
Author(s): Tucci C1, Cioni L1, Mantuano M1, Tettamanti A1
Affiliations(s): 1 QuintilesIMS, Milan, Italy
Publication(s):  ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
Document Type(s): Poster,
Countries: Italy,
C:
Y:
Diabetes, Health policy, Pricing and reimbursement, Regulatory,
2017
  L:
A:
English
Literature Review, Pricing & Reimbursement, Public Health,
  Add to report
 
 
Drug commercialization before the pricing and reimbursement in Italy: the non negotiated C Class (C-nn)
Author(s): Mantuano M1, Cioni L1
Affiliations(s): 1 QuintilesIMS, Milan, Italy
Publication(s):  ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
Document Type(s): Poster,
Countries: Italy,
C:
Y:
Health policy, Pricing and reimbursement, Regulatory,
2017
  L:
A:
English
Literature Review, Pricing & Reimbursement, Public Health,
  Add to report
 
 
 1 of 3 Next Page Last Page